S. Le-guyader-peyrou, Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres des cancers du réseau Francim, vol.2, 2019.

R. L. Siegel, K. D. Miller, and A. Jemal, CA: A, Cancer Journal for Clinicians, vol.68, pp.7-30, 2018.

G. Leone, L. Mele, A. Pulsoni, F. Equitani, and L. Pagano, The incidence of secondary leukemias, Haematologica, vol.84, pp.937-945, 1999.

L. S. Granfeldt-Østgård, Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study, Journal of Clinical Oncology, vol.33, pp.3641-3649, 2015.

A. Zipursky, A. Poon, and J. Doyle, Leukemia in Down Syndrome: A Review. Pediatric Hematology and Oncology, vol.9, pp.139-149, 1992.

E. Estey and H. Döhner, Acute myeloid leukaemia, The Lancet, vol.368, pp.1894-1907, 2006.
URL : https://hal.archives-ouvertes.fr/hal-02874603

R. M. Shallis, R. Wang, A. Davidoff, X. Ma, and A. M. Zeidan, Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges, Blood Reviews, vol.36, pp.70-87, 2019.

M. E. Mcnerney, L. A. Godley, and M. M. Le-beau, Therapy-related myeloid neoplasms: when genetics and environment collide, Nature Reviews Cancer, vol.17, pp.513-527, 2017.

S. M. Smith, Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series, Blood, vol.102, pp.43-52, 2003.

L. B. Travis, Hematopoietic Malignancies and Related Disorders Among Benzene-Exposed Workers in China, Leukemia & Lymphoma, vol.14, pp.91-102, 1994.

E. V. Kane, E. Roman, R. Cartwright, J. Parker, and G. Morgan, Tobacco and the risk of acute leukaemia in adults, British Journal of Cancer, vol.81, pp.1228-1233, 1999.

A. V. Moorman, E. Roman, R. A. Cartwright, and G. J. Morgan, Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups, British Journal of Cancer, vol.86, pp.60-62, 2002.

M. Gundestrup and H. H. Storm, Radiation-induced acute myeloid leukaemia and other cancers in commercial jet cockpit crew: a population-based cohort study, The Lancet, vol.354, pp.2029-2031, 1999.

E. Cardis, Effects of low doses and low dose rates of external ionizing radiation: cancer mortality among nuclear industry workers in three countries, Radiat. Res, vol.142, pp.117-132, 1995.

M. Levi and H. Ten-cate, Disseminated Intravascular Coagulation, New England Journal of Medicine, vol.341, pp.586-592, 1999.

M. S. Cairo and M. Bishop, Tumour lysis syndrome: new therapeutic strategies and classification, British Journal of Haematology, vol.127, pp.3-11, 2004.

H. Döhner, Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, vol.129, pp.424-447, 2017.

J. M. Bennett, Proposals for the Classification of the Acute Leukaemias French-American-British (FAB) Co-operative Group, British Journal of Haematology, vol.33, pp.451-458, 1976.

J. M. Bennett, Proposed Revised Criteria for the Classification of Acute Myeloid Leukemia: A Report of the French-American-British Cooperative Group, Annals of Internal Medicine, vol.103, p.620, 1985.

J. W. Vardiman, N. L. Harris, and R. D. Brunning, The World Health Organization (WHO) classification of the myeloid neoplasms, Blood, vol.100, pp.2292-2302, 2002.

J. W. Vardiman, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, vol.114, pp.937-951, 2009.

D. A. Arber, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, pp.2391-2405, 2016.

H. Döhner, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet, Blood, vol.115, pp.453-474, 2010.

Z. Wang and Z. Chen, Acute promyelocytic leukemia: from highly fatal to highly curable, Blood, vol.111, pp.2505-2515, 2008.

N. A. Sangle and S. L. Perkins, Core-Binding Factor Acute Myeloid Leukemia, Archives of Pathology & Laboratory Medicine, vol.135, pp.1504-1509, 2011.

M. A. Sanz, Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet, Blood, vol.133, pp.1630-1643, 2019.

W. Chen, Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation, Cancer, vol.115, pp.5481-5489, 2009.

C. Gervais, Acute myeloid leukaemia with 8p11 (MYST3) rearrangement: an integrated cytologic, cytogenetic and molecular study by the groupe francophone de cytogénétique hématologique, Leukemia, vol.22, pp.1567-1575, 2008.

J. Sun, De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification, Modern Pathology, vol.24, pp.384-389, 2011.

, MYLOTARG 5 mg, poudre pour solution à diluer pour perfusion -VIDAL 2020, Médicaments

K. Mrózek, N. A. Heerema, and C. D. Bloomfield, Cytogenetics in acute leukemia, Blood Reviews, vol.18, pp.115-136, 2004.

J. P. Patel, Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia, New England Journal of Medicine, vol.366, pp.1079-1089, 2012.

J. C. Byrd, Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461), Blood, vol.100, pp.4325-4336, 2002.

D. Grimwade, Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials, Blood, vol.116, pp.354-365, 2010.

D. A. Breems, Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype, Journal of Clinical Oncology, vol.26, pp.4791-4797, 2008.

P. C. Boddu, Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes, Cancer, vol.125, pp.1091-1100, 2019.

M. Yanada, Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients, Leukemia & Lymphoma, vol.59, pp.601-609, 2018.

E. Papaemmanuil, Genomic Classification and Prognosis in Acute Myeloid Leukemia, New England Journal of Medicine, vol.374, pp.2209-2221, 2016.

J. H. Mendler, RUNX1 Mutations Are Associated With Poor Outcome in Younger and Older Patients With Cytogenetically Normal Acute Myeloid Leukemia and With Distinct Gene and MicroRNA Expression Signatures, Journal of Clinical Oncology, vol.30, pp.3109-3118, 2012.

S. Schnittger, ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome, Leukemia, vol.27, pp.82-91, 2013.

D. Bowen, TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis, Leukemia, vol.23, pp.203-206, 2009.

R. F. Schlenk, The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA, Blood, vol.122, pp.1576-1582, 2013.

S. Schnittger, Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype, Blood, vol.106, pp.3733-3739, 2005.

P. D. Kottaridis, The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials, Blood, vol.98, pp.1752-1759, 2001.

M. Sakaguchi, Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia, Blood Advances, vol.2, pp.2744-2754, 2018.

C. Schoch, W. Kern, S. Schnittger, W. Hiddemann, and T. Haferlach, Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML, Leukemia, vol.18, pp.120-125, 2004.

S. Kayser, The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML, Blood, vol.117, pp.2137-2145, 2011.

M. Othus, Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson, Leukemia, vol.28, pp.289-292, 2014.

J. Koreth, Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Systematic Review and Meta-analysis of Prospective Clinical Trials, JAMA, vol.301, p.2349, 2009.

S. Sengsayadeth, Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission -a review from the Acute Leukemia Working Party of the EBMT, Haematologica, vol.100, pp.859-869, 2015.

S. Kurosawa, Comparison of Allogeneic Hematopoietic Cell Transplantation and Chemotherapy in Elderly Patients with Non-M3 Acute Myelogenous Leukemia in First Complete Remission, Biology of Blood and Marrow Transplantation, vol.17, pp.401-411, 2011.

J. J. Cornelissen and D. Blaise, Hematopoietic stem cell transplantation for patients with AML in first complete remission, Blood, vol.127, pp.62-70, 2016.

M. S. Tallman, All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol, Blood, vol.100, pp.4298-4302, 2002.

X. Chen, Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.33, pp.1258-1264, 2015.

R. B. Walter, Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study, Journal of Clinical Oncology, vol.28, pp.1766-1771, 2010.

W. Cheng, Impact of blood count recovery on outcomes of acute myeloid leukemia patients achieving morphologic leukemia-free state, Blood Cancer Journal, vol.8, 2018.

F. Buccisano, Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia, Blood, vol.119, pp.332-341, 2012.

J. A. Yin, Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial, Blood, vol.120, pp.2826-2835, 2012.

E. Jourdan, Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia, Blood, vol.121, pp.2213-2223, 2013.

D. Araki, Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission, Journal of Clinical Oncology, vol.34, pp.329-336, 2016.

T. J. Lester, J. W. Johnson, and J. Cuttner, Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukemia and hyperleukocytosis, The American Journal of Medicine, vol.79, pp.43-48, 1985.

L. Marbello, Outcome of hyperleukocytic adult acute myeloid leukaemia: A singlecenter retrospective study and review of literature, Leukemia Research, vol.32, pp.1221-1227, 2008.

J. C. Byrd, W. J. Edenfield, D. J. Shields, and N. A. Dawson, Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review, Journal of Clinical Oncology, vol.13, pp.1800-1816, 1995.

M. S. Tallman, Granulocytic sarcoma is associated with the 8;21 translocation in acute myeloid leukemia, Journal of Clinical Oncology, vol.11, pp.690-697, 1993.

C. Schoch, The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups, Haematologica, vol.89, pp.1082-1090, 2004.

T. Büchner, Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group, Journal of Clinical Oncology, vol.27, pp.61-69, 2009.

F. R. Appelbaum, Age and acute myeloid leukemia, Blood, vol.107, pp.3481-3485, 2006.

M. Auerbach, Acute myeloid leukemia in patients more than 50 years of age: Special considerations in diagnosis, treatment, and prognosis, The American Journal of Medicine, vol.96, pp.180-185, 1994.

D. Grimwade, The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties, Blood, vol.92, pp.2322-2333, 1998.

D. Grimwade, The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial, Blood, vol.98, pp.1312-1320, 2001.

R. Stasi, Prognostic value of cytogenetics and multidrug resistance (MDR1) in elderly patients with acute myeloid leukemia, Blood, vol.92, pp.695-697, 1998.

C. L. Willman, Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1), Leukemia, vol.10, issue.1, pp.33-35, 1996.

C. P. Leith, Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study, Blood, vol.89, pp.3323-3329, 1997.

Y. Ofran, M. S. Tallman, and J. M. Rowe, How I treat acute myeloid leukemia presenting with preexisting comorbidities, Blood, vol.128, pp.488-496, 2016.

B. K. Budziszewska, Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study, Leukemia & Lymphoma, vol.56, pp.2331-2338, 2015.

A. Etienne, Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia, Cancer, vol.109, pp.1376-1383, 2007.

M. L. Sorror, Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT, Blood, vol.106, pp.2912-2919, 2005.

M. L. Sorror, Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality, JAMA Oncology, vol.3, p.1675, 2017.

L. S. Østgård, Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study, Leukemia, vol.29, pp.548-555, 2015.

N. J. Short, M. E. Rytting, and J. E. Cortes, Acute myeloid leukaemia, The Lancet, vol.392, pp.593-606, 2018.

M. A. Sanz, Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet, Blood, vol.113, pp.1875-1891, 2009.

P. Montesinos and M. A. Sanz, The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the Literature, Mediterranean Journal of Hematology and Infectious Diseases, vol.3, p.2011059, 2011.

J. W. Yates, H. J. Wallace, R. R. Ellison, and J. F. Holland, Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia, Cancer Chemother Rep, vol.57, pp.485-488, 1973.

H. Döhner, D. J. Weisdorf, and C. D. Bloomfield, Acute Myeloid Leukemia, N Engl J Med, vol.373, pp.1136-1152, 2015.

R. M. Stone, Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation, New England Journal of Medicine, vol.377, pp.454-464, 2017.

J. E. Lancet, CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.36, pp.2684-2692, 2018.

J. J. Cornelissen, The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach, Nature Reviews Clinical Oncology, vol.9, pp.579-590, 2012.

H. Zhu, MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial, Blood, vol.121, pp.4056-4062, 2013.

A. K. Burnett, Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial, Journal of Clinical Oncology, vol.31, pp.3360-3368, 2013.

E. D. Thomas, H. L. Lochte, W. C. Lu, and J. W. Ferrebee, Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and Chemotherapy, New England Journal of Medicine, vol.257, pp.491-496, 1957.

A. Gratwohl, One million haemopoietic stem-cell transplants: a retrospective observational study, The Lancet Haematology, vol.2, pp.91-100, 2015.

S. S. Farag, Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission, Biology of Blood and Marrow Transplantation, vol.17, pp.1796-1803, 2011.

M. Elsawy and M. L. Sorror, Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation, Bone Marrow Transplantation, vol.51, pp.1283-1300, 2016.

B. L. Scott, Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes, Journal of Clinical Oncology, vol.35, pp.1154-1161, 2017.

Y. S. Jethava, Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia, Bone Marrow Transplantation, vol.52, pp.1504-1511, 2017.

B. D. Cheson, Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia, Journal of Clinical Oncology, vol.8, pp.813-819, 1990.

B. D. Cheson, Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, Journal of Clinical Oncology, vol.21, pp.4642-4649, 2003.

, Haute Autorité de Santé -ALD n° 30 -Leucémie aiguë de l'adulte, 2012.

M. R. Baer, High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361), Blood, vol.97, pp.3574-3580, 2001.

G. J. Schuurhuis, Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party, Blood, vol.131, pp.1275-1291, 2018.

R. Kiessling, E. Klein, H. Pross, and H. Wigzell, Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell, European Journal of Immunology, vol.5, pp.117-121, 1975.

G. Trinchieri, Biology of Natural Killer Cells, Advances in Immunology, vol.47, pp.187-376, 1989.

D. Artis and H. Spits, The biology of innate lymphoid cells, Nature, vol.517, pp.293-301, 2015.

E. Vivier, Innate Lymphoid Cells: 10 Years On, Cell, vol.174, pp.1054-1066, 2018.
URL : https://hal.archives-ouvertes.fr/pasteur-02101002

M. A. Cooper, T. A. Fehniger, and M. A. Caligiuri, The biology of human natural killercell subsets, Trends in Immunology, vol.22, pp.633-640, 2001.

N. K. Bjorkstrom, Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education, Blood, vol.116, pp.3853-3864, 2010.

S. Lopez-verges, CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset, Blood, vol.116, pp.3865-3874, 2010.

M. Gumá, Imprint of human cytomegalovirus infection on the NK cell receptor repertoire, Blood, vol.104, pp.3664-3671, 2004.

J. C. Sun, J. N. Beilke, and L. L. Lanier, Adaptive immune features of natural killer cells, Nature, vol.457, pp.557-561, 2009.

A. H. Jonsson and W. M. Yokoyama, Chapter 2 Natural Killer Cell Tolerance, Advances in Immunology, vol.101, pp.27-79, 2009.

J. P. Lodolce, IL-15 Receptor Maintains Lymphoid Homeostasis by Supporting Lymphocyte Homing and Proliferation, Immunity, vol.9, pp.669-676, 1998.

A. M. Abel, C. Yang, M. S. Thakar, and S. Malarkannan, Natural Killer Cells: Development, Maturation, and Clinical Utilization, Front. Immunol, vol.9, p.1869, 2018.

E. Vivier, S. Ugolini, D. Blaise, C. Chabannon, and L. Brossay, Targeting natural killer cells and natural killer T cells in cancer, Nat Rev Immunol, vol.12, pp.239-252, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00685473

E. M. Mace, Cell biological steps and checkpoints in accessing NK cell cytotoxicity, Immunology and Cell Biology, vol.92, pp.245-255, 2014.

I. Voskoboinik, J. C. Whisstock, and J. A. Trapani, Perforin and granzymes: function, dysfunction and human pathology, Nature Reviews Immunology, vol.15, pp.388-400, 2015.

V. Screpanti, R. P. Wallin, H. Ljunggren, and A. Grandien, A Central Role for Death Receptor-Mediated Apoptosis in the Rejection of Tumors by NK Cells, The Journal of Immunology, vol.167, pp.2068-2073, 2001.

L. Zamai, Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells, J. Exp. Med, vol.188, pp.2375-2380, 1998.

C. Fauriat, E. O. Long, H. Ljunggren, and Y. T. Bryceson, Regulation of human NKcell cytokine and chemokine production by target cell recognition, Blood, vol.115, pp.2167-2176, 2010.

E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini, Functions of natural killer cells, Nature Immunology, vol.9, pp.503-510, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00294184

R. Biassoni, Human natural killer cell receptors and co-receptors, Immunol. Rev, vol.181, pp.203-214, 2001.

C. Bottino, Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule, Journal of Experimental Medicine, vol.198, pp.557-567, 2003.

S. Sivori, p46, a Novel Natural Killer Cell-specific Surface Molecule That Mediates Cell Activation, J Exp Med, vol.186, pp.1129-1136, 1997.

A. Pessino, Molecular Cloning of NKp46: A Novel Member of the Immunoglobulin Superfamily Involved in Triggering of Natural Cytotoxicity, J Exp Med, vol.188, pp.953-960, 1998.

A. Moretta, Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis, Annu. Rev. Immunol, vol.19, pp.197-223, 2001.

P. H. Kruse, J. Matta, S. Ugolini, and E. Vivier, Natural cytotoxicity receptors and their ligands, Immunol Cell Biol, vol.92, pp.221-229, 2014.

O. Mandelboim, Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells, Nature, vol.409, pp.1055-1060, 2001.

M. Vitale, NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complexrestricted tumor cell lysis, J. Exp. Med, vol.187, pp.2065-2072, 1998.

H. Spits, Innate lymphoid cells -a proposal for uniform nomenclature, Nat Rev Immunol, vol.13, pp.145-149, 2013.

S. Sivori, NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells, Eur. J. Immunol, vol.29, pp.1656-1666, 1999.

E. Lotzová, C. A. Savary, and R. B. Herberman, Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors, Leukemia Research, vol.11, pp.1059-1066, 1987.

F. Tajima, T. Kawatani, A. Endo, and H. Kawasaki, Natural killer cell activity and cytokine production as prognostic factors in adult acute leukemia, Leukemia, vol.10, pp.478-482, 1996.

M. W. Lowdell, Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells, Br. J. Haematol, vol.117, pp.821-827, 2002.

B. N. Savani, Rapid natural killer cell recovery determines outcome after T-celldepleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia, Leukemia, vol.21, pp.2145-2152, 2007.

L. Ruggeri, Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation, Blood, vol.94, pp.333-339, 1999.

A. Velardi, L. Ruggeri, . Alessandro, . Moretta, and L. Moretta, NK cells: a lesson from mismatched hematopoietic transplantation, Trends Immunol, vol.23, pp.438-444, 2002.

L. Ruggeri, Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants, Science, vol.295, pp.2097-2100, 2002.

L. Ruggeri, Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value, Blood, vol.110, pp.433-440, 2007.

R. T. Costello, Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia, Blood, vol.99, pp.3661-3667, 2002.

C. Fauriat, Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction, Blood, vol.109, pp.323-330, 2007.

B. Sanchez-correa, Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients, Immunol Cell Biol, vol.90, pp.109-115, 2012.

K. Stringaris, Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia, Haematologica, vol.99, pp.836-847, 2014.

D. Sandoval-borrego, Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia, Archives of Medical Research, vol.47, pp.55-64, 2016.

S. Verheyden, M. Bernier, and C. Demanet, Identification of natural killer cell receptor phenotypes associated with leukemia, Leukemia, vol.18, 2002.

A. Chretien, NKp30 expression is a prognostic immune biomarker for stratification of patients with intermediate-risk acute myeloid leukemia, Oncotarget, vol.8, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02517464

C. Pasero, Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer, Oncotarget, vol.6, 2015.

T. Garcia-iglesias, Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions, BMC Cancer, vol.9, 2009.

A. Chretien, NKp46 expression on NK cells as a prognostic and predictive biomarker for response to allo-SCT in patients with AML, OncoImmunology, vol.6, p.1307491, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01789566

S. C. Bendall, Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum, Science, vol.332, pp.687-696, 2011.

S. C. Bendall and G. P. Nolan, From single cells to deep phenotypes in cancer, Nat Biotechnol, vol.30, pp.639-647, 2012.

R. V. Bruggner, B. Bodenmiller, D. L. Dill, R. J. Tibshirani, and G. P. Nolan, Automated identification of stratifying signatures in cellular subpopulations, Proc Natl Acad Sci, vol.111, pp.2770-2777, 2014.

E. I. Kovalenko, M. A. Streltsova, L. M. Kanevskiy, S. A. Erokhina, and W. G. Telford, Identification of Human Memory-Like NK Cells, Curr Protoc Cytom, vol.79, 2017.

A. Baragaño-raneros, C. López-larrea, and B. Suárez-Álvarez, Acute myeloid leukemia and NK cells: two warriors confront each other, OncoImmunology, vol.8, p.1539617, 2019.

A. Chretien, Increased NK Cell Maturation in Patients with Acute Myeloid Leukemia, Frontiers in Immunology, vol.6, 2015.

A. Chretien, Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia, Frontiers in Immunology, vol.8, 2017.

J. Galon and . Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, Science, vol.313, pp.1960-1964, 2006.

B. Han, Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer, Journal of Immunology Research, pp.1-9, 2018.

M. J. Szczepanski, Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors, Cancer Immunol Immunother, vol.59, pp.73-79, 2010.

A. Martner, Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia, OncoImmunology, vol.5, p.1041701, 2016.

H. Vego, Monomethyl fumarate augments NK cell lysis of tumor cells through degranulation and the upregulation of NKp46 and CD107a, Cellular & Molecular Immunology, vol.13, pp.57-64, 2016.

A. Wiernik, Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition, Clinical Cancer Research, vol.19, pp.3844-3855, 2013.

M. Märklin, Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia, j. immunotherapy cancer, vol.7, p.143, 2019.

L. Gauthier, Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity, Cell, vol.177, pp.1701-1713, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02359438

C. Fauriat, Natural Killer Cell-triggering Receptors in Patients with Acute Leukaemia, Leukemia & Lymphoma, vol.44, pp.1683-1689, 2003.

M. Brown and C. Wittwer, Flow Cytometry: Principles and Clinical Applications in Hematology, Clinical Chemistry, vol.46, pp.1221-1229, 2000.

C. Ganzel, Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience, American Journal of Hematology, vol.93, pp.1074-1081, 2018.

E. L. Kaplan and P. Meier, Nonparametric Estimation from Incomplete Observations, J Am Stat Assoc, vol.53, pp.457-481, 1958.

, Etude des sous-populations cellulaires NKp46 + et NKp46 -à l'aide de l'algorithme CITRUS, Annexe, vol.3

, Arbre CITRUS généré à partir des sous-populations cellulaires NK NKp46 + et NKp46 -des VS (n=10) et patients atteints de LAM (n=18), selon l'intensité d'expression des marqueurs CD56, NKG2A, CD16, KIR (CD158a,h et CD158b1,b2,j), pp.57-59

, Chaque noeud représente un ensemble de cellules phénotypiquement similaire, issues des 4 groupes préalablement formés (VS NKp46 + (n=10), VS NKp46 -(n=10), LAM NKp46 + (n=18) et LAM NKp46 -(n=18)

, Survie sans rechute des patients NKp46 high et NKp46 low (A) selon une répartition respective de 19, Annexe, vol.5, p.6

, B) selon le ratio MFI par rapport à l'isotype